(VIANEWS) - The NASDAQ ended the session with Catalyst Pharmaceuticals rising 11.19% to $15.90 on Friday, following the last session's downward trend. NASDAQ jumped 1.26% to $14,963.87, following the last session's downward trend on what was an all-around positive trend trading session today.
Catalyst Pharmaceuticals's last close was $14.30, 35.32% below its 52-week high of $22.11.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Earnings Per Share
As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.55.
PE Ratio
Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 28.91. Meaning, the purchaser of the share is investing $28.91 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.06%.Volume
Today's last reported volume for Catalyst Pharmaceuticals is 1358180 which is 10.89% above its average volume of 1224730.
Moving Average
Catalyst Pharmaceuticals's value is way above its 50-day moving average of $13.37 and way above its 200-day moving average of $13.91.Yearly Top and Bottom Value
Catalyst Pharmaceuticals's stock is valued at $15.90 at 02:04 EST, way below its 52-week high of $22.11 and way higher than its 52-week low of $11.09.
Revenue Growth
Year-on-year quarterly revenue growth grew by 79.4%, now sitting on 348.39M for the twelve trailing months.
More news about Catalyst Pharmaceuticals (CPRX).